Skip to main content
. Author manuscript; available in PMC: 2023 Jun 29.
Published in final edited form as: Nat Med. 2022 Mar 21;28(4):724–734. doi: 10.1038/s41591-022-01726-1

Extended Data Table 1.

Study-related SAEs following CART-PSMA-TGFβRDN cell infusion

SAE Grade
Cohort 2 (n = 3) 1 2 3 4 5
 Cytokine Release Syndrome (CRS) 0 0 2 0 0
 Encephalopathy 0 0 1 0 0
 Syncope 0 0 1 0 0
 Acute Kidney Injury 0 0 1 0 0
 Hypotension 0 0 1 0 0
Cohort 3 (n = 1) 1 2 3 4 5
 Anemia 0 0 1 0 0
 Disseminated Intravascular Coagulation 0 0 1 0 0
 Hepatic Failure 0 0 1 0 0
 Cytokine Release Syndrome 0 0 0 1 0
 Acute Kidney Injury 0 0 0 1 0
 Respiratory Failure 0 0 0 1 0
 Hypotension 0 0 0 1 0
Cohort −3 (n = 6) 1 2 3 4 5
 Cytokine Release Syndrome 1 2 0 0 0
 Upper Respiratory Infection 0 0 1 0 0
 Renal and Urinary Disorders - Other (SIADH*) 0 0 1 0 0
 Hypoxia 0 0 1 0 0
 Hypotension 0 0 1 0 0
*

Syndrome of innaproriate antidiuretic hormone secretion

HHS Vulnerability Disclosure